Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Koehler

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Breast Cancer Research : BCR|December 22, 2010
Deciding priorities in PharmaMaria Koehler
Journal of Pediatric Hematology/Oncology|October 9, 2002
Diminished antibody response to hepatitis B immunization in children with sickle cell diseaseJeffrey Hord, Beth Windsor, Maria Koehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III studyRichard S Finn, Robert Gagnon, Angelo Di Leo, et al.
Mayo Clinic Proceedings|June 6, 2008
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trialsEdith A Perez, Maria Koehler, Julie Byrne, et al.
Anti-Cancer Drugs|March 12, 2004
Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839)Andreas Schneeweiss, Sema Kolay, Sebastian Aulmann, et al.
Cancer Discovery|April 2, 2021
Synthetic Lethality in Cancer Therapeutics: The Next GenerationJeremy Setton, Michael Zinda, Nadeem Riaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancerLeona Downey, Robert B Livingston, Maria Koehler, et al.
Breast Cancer Research and Treatment|January 22, 2008
Pooled analysis of diarrhea events in patients with cancer treated with lapatinibJohn P Crown, Harold A Burris, Fran Boyle, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|January 17, 2015
Cell Index Database (CELLX): a web tool for cancer precision medicineKeith A Ching, Kai Wang, Zhengyan Kan, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Breast Cancer Research : BCR|December 22, 2010
Deciding priorities in PharmaMaria Koehler
Journal of Pediatric Hematology/Oncology|October 9, 2002
Diminished antibody response to hepatitis B immunization in children with sickle cell diseaseJeffrey Hord, Beth Windsor, Maria Koehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III studyRichard S Finn, Robert Gagnon, Angelo Di Leo, et al.
Mayo Clinic Proceedings|June 6, 2008
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trialsEdith A Perez, Maria Koehler, Julie Byrne, et al.
Anti-Cancer Drugs|March 12, 2004
Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839)Andreas Schneeweiss, Sema Kolay, Sebastian Aulmann, et al.
Cancer Discovery|April 2, 2021
Synthetic Lethality in Cancer Therapeutics: The Next GenerationJeremy Setton, Michael Zinda, Nadeem Riaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancerRichard S Finn, Michael F Press, Judy Dering, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancerLeona Downey, Robert B Livingston, Maria Koehler, et al.
Breast Cancer Research and Treatment|January 22, 2008
Pooled analysis of diarrhea events in patients with cancer treated with lapatinibJohn P Crown, Harold A Burris, Fran Boyle, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|January 17, 2015
Cell Index Database (CELLX): a web tool for cancer precision medicineKeith A Ching, Kai Wang, Zhengyan Kan, et al.
Pageof 4